Filtered By:
Source: Cardiology Journal
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 265 results found since Jan 2013.
Is transesophageal echocardiography necessary before electrical cardioversion in patients treated with non-vitamin K antagonist oral anticoagulants? Current evidence and practical approach
Cardiol J. 2021 Oct 21. doi: 10.5603/CJ.a2021.0129. Online ahead of print.ABSTRACTAccording to current guidelines, non-vitamin K antagonist oral anticoagulants (NOACs) should be used at least 3 weeks before planned electrical cardioversion. In accordance with international atrial fibrillation (AF) guidelines, transesophageal echocardiography (TEE) is a pre-procedural examination recommended as an alternative to adequate oral anticoagulation. The strategy related to qualifying patients treated with NOACs for pre-procedural TEE differs in individual centers. Therefore, it is necessary to create an algorithm that will standar...
Source: Cardiology Journal - October 21, 2021 Category: Cardiology Authors: Iwona Gorczyca Beata Uzi ębło-Życzkowska Pawe ł Krzesiński Agnieszka Major Agnieszka Kap łon-Cieślicka Source Type: research
Need to update cardiological guidelines to prevent COVID-19 related myocardial infarction and ischemic stroke
Cardiol J. 2021 Oct 13. doi: 10.5603/CJ.a2021.0120. Online ahead of print.NO ABSTRACTPMID:34642925 | DOI:10.5603/CJ.a2021.0120
Source: Cardiology Journal - October 13, 2021 Category: Cardiology Authors: Gabriella Nucera Francesco Chirico Zubaid Rafique Natasza Gilis-Malinowska Aleksandra Gasecka Nataliia Litvinova Benjamin Wang Olayinka Ilesanmi Michal Pruc Milosz J Jaguszewski Lukasz Szarpak Source Type: research
Transcatheter aortic valve implantation results are not superimposable to surgery in patients with aortic stenosis at low surgical risk
CONCLUSIONS: TAVI and SVAR in the treatment of AS in the patients at low surgical risk are not superimposable. In particular, if 30-day and 1-year mortality, major bleeding and acute kidney injury were significantly lower for TAVI, the need of new PM implantation and paravalvular leak were significantly lower in SAVR. Consequently, we suggest the need of more trials to evaluate the effectiveness of TAVI as routine therapeutic procedure in the treatment of patients with low surgical risk AS.PMID:34622437 | DOI:10.5603/CJ.a2021.0114
Source: Cardiology Journal - October 8, 2021 Category: Cardiology Authors: Maria Cristina Acconcia Marco Alfonso Perrone Domenico Sergi Marco Di Luozzo Massimo Marchei Pasquale De Vico Antonio Sili Scavalli Giuseppe Pannarale Marcello Chiocchi Carlo Gaudio Francesco Romeo Quintilio Caretta Francesco Barill à Source Type: research
